Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium

Tao Liu, Tamorah Lewis, Estelle B Gauda, Jogarao Gobburu, Vijay Ivaturi

Research output: Contribution to journalArticle

Abstract

Conducting and analyzing clinical trials in vulnerable neonates are extremely challenging. The aim of this analysis is to develop a morphine population pharmacokinetics (PK) model using data collected during a randomized control trial in neonates with abstinence syndrome (NAS). A 3-compartment morphine structural PK model after intravenous (IV) administration from previously published work was utilized as prior, whereas an allometric scaling method with physiological consideration was used to extrapolate a PK profile from adults to pediatrics. The absorption rate constant and bioavailability were estimated in NAS after oral administration of diluted tincture of opium (DTO). Goodness-of-fit plots along with normalized prediction distribution error and bootstrap method were performed for model evaluation. We successfully extrapolated the PK profile from adults to pediatrics after IV administration. The estimated first-order absorption rate constant and bioavailability were 0.751 hour−1 and 48.5%, respectively. Model evaluations showed that the model can accurately and precisely describe the observed data. The population pharmacokinetic model we derived for morphine after oral administration of DTO is reasonable and acceptable; therefore, it can be used to describe the PK and guide future studies. The integration of the previous population PK knowledge as prior information successfully overcomes the logistic and practical issue in vulnerable neonate population.

Original languageEnglish (US)
Pages (from-to)1009-1018
Number of pages10
JournalJournal of Clinical Pharmacology
DOIs
StatePublished - Aug 1 2016

Fingerprint

Opium
Morphine
Oral Administration
Pharmacokinetics
Newborn Infant
Population
Intravenous Administration
Biological Availability
Pediatrics
Structural Models
Vulnerable Populations
Clinical Trials

Keywords

  • bioavailability
  • diluted tincture of opium
  • morphine
  • neonatal abstinence syndrome
  • neonate
  • population pharmacokinetic model

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium. / Liu, Tao; Lewis, Tamorah; Gauda, Estelle B; Gobburu, Jogarao; Ivaturi, Vijay.

In: Journal of Clinical Pharmacology, 01.08.2016, p. 1009-1018.

Research output: Contribution to journalArticle

@article{808247e82290436c8cd37663864cb4f9,
title = "Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium",
abstract = "Conducting and analyzing clinical trials in vulnerable neonates are extremely challenging. The aim of this analysis is to develop a morphine population pharmacokinetics (PK) model using data collected during a randomized control trial in neonates with abstinence syndrome (NAS). A 3-compartment morphine structural PK model after intravenous (IV) administration from previously published work was utilized as prior, whereas an allometric scaling method with physiological consideration was used to extrapolate a PK profile from adults to pediatrics. The absorption rate constant and bioavailability were estimated in NAS after oral administration of diluted tincture of opium (DTO). Goodness-of-fit plots along with normalized prediction distribution error and bootstrap method were performed for model evaluation. We successfully extrapolated the PK profile from adults to pediatrics after IV administration. The estimated first-order absorption rate constant and bioavailability were 0.751 hour−1 and 48.5{\%}, respectively. Model evaluations showed that the model can accurately and precisely describe the observed data. The population pharmacokinetic model we derived for morphine after oral administration of DTO is reasonable and acceptable; therefore, it can be used to describe the PK and guide future studies. The integration of the previous population PK knowledge as prior information successfully overcomes the logistic and practical issue in vulnerable neonate population.",
keywords = "bioavailability, diluted tincture of opium, morphine, neonatal abstinence syndrome, neonate, population pharmacokinetic model",
author = "Tao Liu and Tamorah Lewis and Gauda, {Estelle B} and Jogarao Gobburu and Vijay Ivaturi",
year = "2016",
month = "8",
day = "1",
doi = "10.1002/jcph.696",
language = "English (US)",
pages = "1009--1018",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium

AU - Liu, Tao

AU - Lewis, Tamorah

AU - Gauda, Estelle B

AU - Gobburu, Jogarao

AU - Ivaturi, Vijay

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Conducting and analyzing clinical trials in vulnerable neonates are extremely challenging. The aim of this analysis is to develop a morphine population pharmacokinetics (PK) model using data collected during a randomized control trial in neonates with abstinence syndrome (NAS). A 3-compartment morphine structural PK model after intravenous (IV) administration from previously published work was utilized as prior, whereas an allometric scaling method with physiological consideration was used to extrapolate a PK profile from adults to pediatrics. The absorption rate constant and bioavailability were estimated in NAS after oral administration of diluted tincture of opium (DTO). Goodness-of-fit plots along with normalized prediction distribution error and bootstrap method were performed for model evaluation. We successfully extrapolated the PK profile from adults to pediatrics after IV administration. The estimated first-order absorption rate constant and bioavailability were 0.751 hour−1 and 48.5%, respectively. Model evaluations showed that the model can accurately and precisely describe the observed data. The population pharmacokinetic model we derived for morphine after oral administration of DTO is reasonable and acceptable; therefore, it can be used to describe the PK and guide future studies. The integration of the previous population PK knowledge as prior information successfully overcomes the logistic and practical issue in vulnerable neonate population.

AB - Conducting and analyzing clinical trials in vulnerable neonates are extremely challenging. The aim of this analysis is to develop a morphine population pharmacokinetics (PK) model using data collected during a randomized control trial in neonates with abstinence syndrome (NAS). A 3-compartment morphine structural PK model after intravenous (IV) administration from previously published work was utilized as prior, whereas an allometric scaling method with physiological consideration was used to extrapolate a PK profile from adults to pediatrics. The absorption rate constant and bioavailability were estimated in NAS after oral administration of diluted tincture of opium (DTO). Goodness-of-fit plots along with normalized prediction distribution error and bootstrap method were performed for model evaluation. We successfully extrapolated the PK profile from adults to pediatrics after IV administration. The estimated first-order absorption rate constant and bioavailability were 0.751 hour−1 and 48.5%, respectively. Model evaluations showed that the model can accurately and precisely describe the observed data. The population pharmacokinetic model we derived for morphine after oral administration of DTO is reasonable and acceptable; therefore, it can be used to describe the PK and guide future studies. The integration of the previous population PK knowledge as prior information successfully overcomes the logistic and practical issue in vulnerable neonate population.

KW - bioavailability

KW - diluted tincture of opium

KW - morphine

KW - neonatal abstinence syndrome

KW - neonate

KW - population pharmacokinetic model

UR - http://www.scopus.com/inward/record.url?scp=84978394467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978394467&partnerID=8YFLogxK

U2 - 10.1002/jcph.696

DO - 10.1002/jcph.696

M3 - Article

C2 - 26712409

AN - SCOPUS:84978394467

SP - 1009

EP - 1018

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -